9 results about "Vertebrate" patented technology

The present invention relates to improved LAMP constructs comprising cancer antigens. Specifically, improved LAMP constructs comprising specific fragments of LAMP endodomain are provided to deliver cancer antigens to immune cells for enhanced processing. These LAMP constructs are useful in the treatment of diseases, in particular hyperproliferative disorders and / or cancer. The improved LAMP constructs, when administered to a subject, allow presentation of a correctly configured three-dimensional epitope for generating an immune response. The improved LAMP constructs may be multivalent molecules, and / or may be provided as part of multivalent vaccines containing two or more LAMP constructs. The improved LAMP constructs described herein can also be used to produce antibodies when administered to non-human vertebrates.

The present invention provides improved LAMP Constructs comprising specific fragments of the LAMP lumenal domain to deliver cancer antigens to immune cells for enhanced processing. These LAMP Constructs can be used for the treatment of disease and in particular hyperproliferative disorders and / or cancer. The improved LAMP Constructs allow for presentation of properly configured three dimensional epitopes for production of an immune response when administered to a subject. The improved LAMP Constructs can be multivalent molecules, and / or can be provided as part of a multivalent vaccine containing two or more LAMP Constructs. The improved LAMP Constructs as described herein can also be used to generate antibodies when administered to a non-human vertebrate.

Provided are a one-step extraction kit, an extraction method, and a high-throughput sequencing method for vertebrate mitochondrial genomic DNA and the use thereof. The kit comprises: a reagent A comprising 3.25-4.75M guanidinium isothiocyanate, 0.65-0.85M sodium citrate, and 5-15v / v% sodium N-lauroyl sarcosinate as a cell lysis and equilibration reagent; a reagent B comprising sodium acetate; and a reagent C comprising phenol, chloroform and isoamyl alcohol at a volume ratio of (120-130) : (19-29) : 1. Reagents B and C are used for mixing with a sample of the total DNA from the lysed cells and undergoing phase separation so as to obtain the aqueous phase of the mitochondrial DNA.

The invention relates to blunt-snout bream terminal deoxynucleotidyl transferase and application thereof, and belongs to the technical field of gene engineering. The invention provides Branchiostoma belcheri terminal deoxynucleotidyl transferase (BbeTdT). The amino acid sequence of the Branchiostoma belcheri terminal deoxynucleotidyl transferase (BbeTdT) is shown as SEQ ID NO: 2 or SEQ ID NO: We find that terminal deoxynucleotidyl transferase (TdT) derived from Branchiostoma belcheri not only has terminal transferase activity under in vitro conditions, but also has nucleotide preference different from that of TdT of vertebrates. The BbeTdT has better selectivity aiming at a specific sequence or a terminal structure, and non-specific addition can be reduced in a practical application process, so that complementation with mammal TdT is formed, and the BbeTdT is suitable for industrial processes needing different preferences. In addition, the BbeTdT mutant is constructed, the activity of the terminal transferase of the BbeTdT mutant is higher, and the engineering transformation potential of the BbeTdT is further optimized.

Antimicrobial modified defensin or defensin-like peptides, modified C-terminal fragments of defensins or defensin-like peptides, and nucleic acids encoding them are disclosed. Compositions containing the defensin mutant peptides and methods of using them to control microbial infections in plants and vertebrates, and to control feed and food contamination are also disclosed.

Pharmaceutical and / or cosmetic formulations containing artificial peptides and their medical uses are described, the artificial peptides being characterized by proline sequences that are ubiquitous in key stromal cell proteins involved in wound healing, bone and cartilage formation, and the maintenance of connective tissue in all vertebrates. This invention relates to a pharmaceutical formulation in gel form, comprising a. a substance comprising Pro-X-X-Pro-Y-Y-Y-Pro-X-X-Pro-Y-Y-Pro-X-X-Pro-Y-Y-Y-Y-Pro-Y-Y-Y-Pro-Y-Y-Y-Y-Pro-X-X-Pro-X-Pro-Y-Y-Y-Y-Pro-X-X-Pro-Y-Y-Y-Pro-Y-Y-Pro-X-X-Pro-Y-Y-Pro-Y-Pro-X-X-Pro-Y-Pro-Y-Pro-X-X-Pro-Y-Pro-Y-Pro-X-X-Pro-Y-Y-Pro-X-X-Pro-Y-X ... Artificial peptides comprising the amino acid sequence of NO:1) and / or artificial peptides comprising or composed of the amino acid sequence Pro-X-X-Pro-Y-Y-Pro-X-X-Pro-Y-Y-Pro-X-X-Pro-Y-Y-Pro-X-Pro-X-Pro-Pro (SEQ ID NO:2), wherein i) Pro is proline; ii) X is an amino acid selected from Ala, Ile, Leu, Met, Phe, Trp and Val; iii) Y is an amino acid selected from Asn, Cys, Gln, Ser, Thr and Tyr; b. cross-linked hyaluronic acid fibers (HA-XL) and c. linear hyaluronic acid fibers (HA).

The invention relates to sponge terminal deoxynucleotidyl transferase and application thereof, and belongs to the technical field of genetic engineering. The invention provides sponge terminal deoxynucleotidyl transferase. The amino acid sequence of the sponge terminal deoxynucleotidyl transferase is shown as SEQ ID NO: 2. It is found that AquTdT derived from coral sponge not only has terminal deoxynucleotidyl transferase activity under in vitro conditions, but also has different nucleotide transfer preference from TdT derived from vertebrates. Therefore, the AquTdT has better selectivity for a specific sequence or a terminal structure, and non-specific addition can be reduced in a practical application process, so that complementation with mammal TdT is formed, and the method is suitable for industrial processes needing different preferences.

The present application relates to the field of biotechnology, and particularly relates to a novel mosquito-specific virus strain and application thereof. The strain has a preservation number of CCTCC NO: V202643, and is identified as a new species of Dinurina virus. The present application discloses that the strain can efficiently inhibit the replication of various mosquito-borne viruses in mosquito cells, thereby weakening the ability of mosquitoes to spread mosquito-borne viruses. In addition, the host range of the strain is strictly limited to mosquitoes, and the strain is not infectious to vertebrates including humans. The present application also discloses a combined use scheme of the strain and another mosquito-specific virus. The synergistic blocking effect can be produced by co-infection of the two viruses in Aedes mosquitoes, and the two viruses have important application value in the targeted prevention and control of mosquito-borne viruses.

The present invention pertains to the field of biotechnology, nutrition and protein synthesis. More specifically, the invention discloses a food additive, the use thereof, a process for the solid-phase synthesis of a peptide providing a reduction in the generation of toxic by-products, a food and / or food supplement formulation comprising said additive and / or supplement. In one embodiment, said peptide is of SEQ ID NO: 1, Asp-Ile-Ile-Ala-Asp-Asp-Glu-Pro-Leu-Thr, or DIIADDEPLT, also known as Pep19 or WATACAP. The food additive and / or supplement of the invention comprises said peptide and provides essential amino acids that promote metabolic improvements in vertebrates, including humans and dogs.